<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567084</url>
  </required_header>
  <id_info>
    <org_study_id>POZNAN-UMS-JK1</org_study_id>
    <nct_id>NCT02567084</nct_id>
  </id_info>
  <brief_title>Complete Twelve Month Bone Remodeling With a Bi-phasic Injectable Bone Substitute in Benign Bone Tumors</brief_title>
  <acronym>BRBBT</acronym>
  <official_title>A Prospective, Longitudinal Patient Study on CERAMENT™|BONE VOID FILLER in Benign Bone Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the ability a injectable bi-phasic ceramic bone
      substitute to provide bone generation and bone remodeling in patients with benign bone
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to assess the usefulness of injectable bi-phasic ceramic bone
      substitute (CERAMENT™ |BONE VOID FILLER) in patients with benign bone tumors. The primary
      objectives is to:

        1. Assess the ability of bi-phasic ceramic bone substitute to provide bone generation and
           bone remodeling in patients with benign bone tumors.

        2. Assess the safety of bi-phasic ceramic bone substitute as measured by device
           complaint/Adverse Events monitoring and documentation of subsequent surgical procedure.

        3. In the case of bone cysts assess the ability of bi-phasic ceramic bone substitute to
           transform into bone and possibly induce bone formation in regions of the cyst not filled
           with the product.

      Benign bone tumors are often treated with intralesional curettage which creates a bone defect
      that can be filled with e.g. demineralized bone matrix, autologous bone, ceramic bone
      substitutes or polymethylmetacrylate cement.

      Autograft has been considered the golden standard because it possesses all three of the
      essential elements required for an optimal bone graft, but is associated with morbidity at
      the donor site and is limited in supply. Allograft has been employed as a good alternative to
      autograft but the concern for potential disease transmission remains. Synthetic bone graft
      substitutes have been gaining popularity as viable alternatives for void and defect filling
      eliminating the concerns with autograft and allograft. These synthetic bone substitutes have
      invariably been based on calcium phosphate and/or calcium sulfate materials which are
      osteoconductive and facilitate bone remodeling, although side effects such as drainage and
      wound complications slow remodeling to bone or negligible bone generation have limited their
      use. Thus, new synthetic bone substitutes with described positive effects in vertebroplasty,
      osteotomy, and smaller trauma defects merit further investigation also in treatment of larger
      bone defects.

      In a prospective series, patients with benign bone tumors were treated by minimal invasive
      intervention with a bi-phasic and injectable ceramic bone substitute (CERAMENT™ BONE VOID
      FILLER), composed of 60% weight synthetic calcium sulfate (CaS) and 40% weight hydroxyapatite
      (HA) powder was mixed with a water-soluble radio-contrast agent iohexol (180 mg/ml) to make
      the material radiopaque. The defects were treated by either mini-invasive surgery (solid
      tumors) or percutaneous injection (cysts) and followed clinically and radiologically for 12
      months. CT scan was performed after 12 months to confirm bone remodeling of the bone
      substitute. All patients were allowed full weight bearing immediately after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone remodeling according to Neer classification</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Evaluate bone healing and remodeling at 12 month by X-ray and CT-scan using Modified Neer classification of radiological results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cyst and bone formation volume</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Calculate the pre-operative volume of the cyst, document the volume of product placed into the cyst and the volume of bone formed at 12 months.
In the case of bone cysts assess the ability of CERAMENT™ |BONE VOID FILLER to transform into bone and possibly induce bone formation in regions of the cyst not filled with the product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Assess the safety of CERAMENT™|BONE VOID FILLER as measured by number of any device complaint/Adverse Event and any subsequent surgical procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Bone Cyst</condition>
  <arm_group>
    <arm_group_label>CERAMENT™ |BONE VOID FILLER</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CERAMENT™ |BONE VOID FILLER</intervention_name>
    <description>Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.</description>
    <arm_group_label>CERAMENT™ |BONE VOID FILLER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the hospital for surgical treatment of benign bone lesion
             requiring bone grafting.

        Exclusion Criteria:

          -  Patient below 6 years of ageIrreversible coagulopathy or bleeding disorder. Note
             regarding reversible coagulopathies: Patients on coumarin or other anticoagulants may
             participate. Investigators should follow routine practices for perioperative
             discontinuation and re-initiation of anticoagulants;

          -  A pre-existing calcium metabolism disorder (e.g. hypercalcemia).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Kaczmarczyk, Prof.MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan Medical University</affiliation>
  </overall_official>
  <reference>
    <citation>Mik G, Arkader A, Manteghi A, Dormans JP. Results of a minimally invasive technique for treatment of unicameral bone cysts. Clin Orthop Relat Res. 2009 Nov;467(11):2949-54. doi: 10.1007/s11999-009-1008-2. Epub 2009 Aug 4.</citation>
    <PMID>19653053</PMID>
  </reference>
  <reference>
    <citation>Khan SN, Tomin E, Lane JM. Clinical applications of bone graft substitutes. Orthop Clin North Am. 2000 Jul;31(3):389-98. Review.</citation>
    <PMID>10882465</PMID>
  </reference>
  <reference>
    <citation>Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am. 2011 Dec 7;93(23):2227-36. doi: 10.2106/JBJS.J.01513. Review.</citation>
    <PMID>22159859</PMID>
  </reference>
  <reference>
    <citation>Hinsenkamp M, Muylle L, Eastlund T, Fehily D, Noël L, Strong DM. Adverse reactions and events related to musculoskeletal allografts: reviewed by the World Health Organisation Project NOTIFY. Int Orthop. 2012 Mar;36(3):633-41. doi: 10.1007/s00264-011-1391-7. Epub 2011 Nov 3. Review.</citation>
    <PMID>22048753</PMID>
  </reference>
  <reference>
    <citation>Lee GH, Khoury JG, Bell JE, Buckwalter JA. Adverse reactions to OsteoSet bone graft substitute, the incidence in a consecutive series. Iowa Orthop J. 2002;22:35-8.</citation>
    <PMID>12180608</PMID>
  </reference>
  <reference>
    <citation>Ferguson JY, Dudareva M, Riley ND, Stubbs D, Atkins BL, McNally MA. The use of a biodegradable antibiotic-loaded calcium sulphate carrier containing tobramycin for the treatment of chronic osteomyelitis: a series of 195 cases. Bone Joint J. 2014 Jun;96-B(6):829-36. doi: 10.1302/0301-620X.96B6.32756.</citation>
    <PMID>24891586</PMID>
  </reference>
  <reference>
    <citation>Reppenhagen S, Reichert JC, Rackwitz L, Rudert M, Raab P, Daculsi G, Nöth U. Biphasic bone substitute and fibrin sealant for treatment of benign bone tumours and tumour-like lesions. Int Orthop. 2012 Jan;36(1):139-48. doi: 10.1007/s00264-011-1282-y. Epub 2011 May 28.</citation>
    <PMID>21626113</PMID>
  </reference>
  <reference>
    <citation>Fillingham YA, Lenart BA, Gitelis S. Function after injection of benign bone lesions with a bioceramic. Clin Orthop Relat Res. 2012 Jul;470(7):2014-20. doi: 10.1007/s11999-012-2251-5.</citation>
    <PMID>22290129</PMID>
  </reference>
  <reference>
    <citation>Petruskevicius J, Nielsen S, Kaalund S, Knudsen PR, Overgaard S. No effect of Osteoset, a bone graft substitute, on bone healing in humans: a prospective randomized double-blind study. Acta Orthop Scand. 2002 Oct;73(5):575-8.</citation>
    <PMID>12440503</PMID>
  </reference>
  <reference>
    <citation>Hatten HP Jr, Voor MJ. Bone healing using a bi-phasic ceramic bone substitute demonstrated in human vertebroplasty and with histology in a rabbit cancellous bone defect model. Interv Neuroradiol. 2012 Mar;18(1):105-13. Epub 2012 Mar 16.</citation>
    <PMID>22440608</PMID>
  </reference>
  <reference>
    <citation>Masala S, Nano G, Marcia S, Muto M, Fucci FP, Simonetti G. Osteoporotic vertebral compression fracture augmentation by injectable partly resorbable ceramic bone substitute (Cerament™|SPINESUPPORT): a prospective nonrandomized study. Neuroradiology. 2012 Nov;54(11):1245-51. doi: 10.1007/s00234-012-1016-x. Epub 2012 Mar 6.</citation>
    <PMID>22391680</PMID>
  </reference>
  <reference>
    <citation>Abramo A, Geijer M, Kopylov P, Tägil M. Osteotomy of distal radius fracture malunion using a fast remodeling bone substitute consisting of calcium sulphate and calcium phosphate. J Biomed Mater Res B Appl Biomater. 2010 Jan;92(1):281-6. doi: 10.1002/jbm.b.31524.</citation>
    <PMID>19904822</PMID>
  </reference>
  <reference>
    <citation>Nilsson M, Zheng MH, Tägil M. The composite of hydroxyapatite and calcium sulphate: a review of preclinical evaluation and clinical applications. Expert Rev Med Devices. 2013 Sep;10(5):675-84. doi: 10.1586/17434440.2013.827529. Review. Erratum in: Expert Rev Med Devices. 2013 Nov;10(6):857.</citation>
    <PMID>24053255</PMID>
  </reference>
  <reference>
    <citation>Sung AD, Anderson ME, Zurakowski D, Hornicek FJ, Gebhardt MC. Unicameral bone cyst: a retrospective study of three surgical treatments. Clin Orthop Relat Res. 2008 Oct;466(10):2519-26. doi: 10.1007/s11999-008-0407-0. Epub 2008 Aug 5.</citation>
    <PMID>18679761</PMID>
  </reference>
  <reference>
    <citation>Cho HS, Seo SH, Park SH, Park JH, Shin DS, Park IH. Minimal invasive surgery for unicameral bone cyst using demineralized bone matrix: a case series. BMC Musculoskelet Disord. 2012 Jul 29;13:134. doi: 10.1186/1471-2474-13-134.</citation>
    <PMID>22839754</PMID>
  </reference>
  <reference>
    <citation>Campanacci M, Capanna R, Fabbri N, Bettelli G. Curettage of giant cell tumor of bone. Reconstruction with subchondral grafts and cement. Chir Organi Mov. 1990;75(1 Suppl):212-3.</citation>
    <PMID>2249537</PMID>
  </reference>
  <reference>
    <citation>Bickels J, Meller I, Shmookler BM, Malawer MM. The role and biology of cryosurgery in the treatment of bone tumors. A review. Acta Orthop Scand. 1999 Jun;70(3):308-15. Review.</citation>
    <PMID>10429612</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>M.D Maciej Goch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bone substitute</keyword>
  <keyword>benign bone cyst</keyword>
  <keyword>ceramic</keyword>
  <keyword>remodelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Cysts</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

